Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P20226 (
TATA-binding protein
)
1,297
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Emerging evidence supports the idea that the c-Jun N-terminal kinases (JNKs) possess overlapping but distinct functions. The potential roles of the ubiquitously expressed JNK1 and
JNK2
in regulating expression of the central transcription initiation factor,
TATA-binding protein
(
TBP
), were examined. Relative to wild-type fibroblasts,
TBP
was decreased in Jnk1(-/-) cells and increased in Jnk2(-/-) cells. Similarly, reduction of JNK1 in human hepatoma cells decreased
TBP
expression, whereas reduction of
JNK2
enhanced it. JNK-mediated regulation of
TBP
expression occurs at the transcriptional level through their ability to target Elk-1, which directly regulates the
TBP
promoter in response to epidermal growth factor stimulation. JNK1 increases, whereas
JNK2
decreases, the phosphorylation state of Elk-1, which differentially affects Elk-1 occupancy at a defined site within the
TBP
promoter. These JNK-mediated alterations in
TBP
expression, alone, serve to regulate c-Jun expression and fibroblast proliferation rates. These studies uncovered several new molecular events that distinguish the functions of JNK1 and
JNK2
that are critical for their regulation of cellular proliferation.
...
PMID:TBP is differentially regulated by c-Jun N-terminal kinase 1 (JNK1) and JNK2 through Elk-1, controlling c-Jun expression and cell proliferation. 1707 9